Ailux Biologics
Private Company
Total funding raised: $5M
Overview
Ailux Biologics is a private, pre-clinical stage biotechnology company founded in 2020, leveraging an end-to-end AI platform for biologics discovery and design. Its core asset is the AtlaX™ multi-modal biologics database, which powers three foundational AI models to generate and optimize therapeutic candidates, with a pipeline focused on antibody-based therapies for hard-to-treat conditions. The company has established significant validation through strategic collaborations with major pharmaceutical firms like Eli Lilly, UCB, and Janssen Biotech, positioning it as a promising player in the AI-driven drug discovery space.
Technology Platform
End-to-end AI-driven platform built on the proprietary AtlaX™ multi-modal biologics database. It features three foundational AI models for generative and predictive tasks, applied to hit generation, lead optimization, and the design of molecules against hard targets, with advanced engineering and multispecifics capabilities. Fully integrated with wet lab for iterative design-test cycles.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Ailux competes in the crowded AI drug discovery sector against public companies like Recursion, Exscientia, and AbCellera, as well as numerous private peers. Its specific focus on biologics and antibodies places it against specialists such as BigHat Biosciences and Absci. Its key differentiators are its integrated wet-lab capabilities, the AtlaX™ database incorporating negative data, and its validation through multiple top-tier pharma partnerships.